Previous 10 | Next 10 |
Summary Last month, ZYME presented strong data in HER2+ BTC. Its Jazz collaboration has given it access to a lot of funds. The stock is still stagnant, probably because the market feels ZYME lacks growth prospects. For further details see: Zymeworks: Good D...
Summary Today, we circle back on Zymeworks Inc. and update our analysis to account for recent events. A recent license agreement has left the company flush with cash as it continues to advance its lead candidate. An investment analysis follows in the paragraphs below. ...
Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...
Zymeworks ( NASDAQ: ZYME ) said based on its current operational plans, it will have enough cash to fund R&D and operations through at least 2026 . The company said it ended 2022 with cash of $490M. In 2023, it expects cash burn of $90M-$120M. The biotech is also reorganiz...
Provides updated key priorities and focus on enterprise value framework Closing of Jazz Pharmaceuticals (Jazz) collaboration in fourth quarter completes financial transformation initiatives originally planned for 2022 Announces additional financial guidance on expected cash runway...
Summary Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading ...
Zanidatamab as monotherapy produced a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC) Pending receipt of regulatory approvals, zanidatamab has the pot...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal a...
Summary Two new Breakout Stocks for Week 50 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +131.5% YTD. This week 1 of 4 high frequency breakout picks gained over 10% in less than a week with peak gains in VITL +10.4% while PBT...
Results show overall confirmed objective response rate (cORR) of 33%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 9.6 months Data support further investigation of zanidatamab in combination with palbociclib and fulvestrant as a potential chemotherapy-...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...